Selected article for: "activity indicate and acute respiratory syndrome"
Author: Keyaerts, Els; Vijgen, Leen; Maes, Piet; Neyts, Johan; Ranst, Marc Van
Title: In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
  • Cord-id: 5lzzobl3
  • Document date: 2004_10_8
    • ID: 5lzzobl3
    Snippet: We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a clinically approved drug effective against malaria. We tested chloroquine phosphate for its antiviral potential against SARS-CoV-induced cytopathicity in Vero E6 cell culture. Results indicate that the IC(50) of chloroquine for antiviral activity (8.8 ± 1.2 μM) was significantly lower than its cytostatic activity;
    Document: We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a clinically approved drug effective against malaria. We tested chloroquine phosphate for its antiviral potential against SARS-CoV-induced cytopathicity in Vero E6 cell culture. Results indicate that the IC(50) of chloroquine for antiviral activity (8.8 ± 1.2 μM) was significantly lower than its cytostatic activity; CC(50) (261.3 ± 14.5 μM), yielding a selectivity index of 30. The IC(50) of chloroquine for inhibition of SARS-CoV in vitro approximates the plasma concentrations of chloroquine reached during treatment of acute malaria. Addition of chloroquine to infected cultures could be delayed for up to 5 h postinfection, without an important drop in antiviral activity. Chloroquine, an old antimalarial drug, may be considered for immediate use in the prevention and treatment of SARS-CoV infections.

    Search related documents:
    Co phrase search for related documents
    • active component and addition drug: 1, 2, 3
    • active component and addition drug time: 1, 2, 3
    • active component and addition time: 1, 2, 3, 4, 5
    • active component and addition time assay: 1
    • active component and lopinavir ritonavir: 1
    • active component and lung injury: 1, 2
    • acute malaria and administer easy: 1
    • acute malaria and lung injury: 1, 2
    • acute respiratory syndrome and addition drug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and addition drug time: 1, 2, 3, 4
    • acute respiratory syndrome and addition drug time assay: 1, 2
    • acute respiratory syndrome and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and addition time assay: 1, 2, 3, 4
    • acute respiratory syndrome and administer easy: 1
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir protease inhibitor: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • addition drug and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
    • addition drug and lung injury: 1